Improvements in multiple sign efficacy endpoints were reported for licaminlimab in patients with dry eye disease, with more pronounced effects in patients with a TNFR1 genetic biomarker, according to an Oculis press release.
“I am very excited to see that licaminlimab, with its dual anti-inflammatory and anti-apoptotic mechanism of action, targets the origin of DED and has the potential to be truly disease modifying as shown by improvements in several clinical signs of DED, including corneal staining,” Christophe Baudouin, MD, PhD, a member of the Oculis scientific advisory board,